This article and associated images are based on a poster originally authored by Denise Sullivan, Zhong Yu, Benjamin Streeter, Stacie Chvatal and Daniel Millard and presented at ELRIG Drug Discovery ...

Medical device manufacturers use cytotoxicity testing to help prove that devices that come into contact with the human body are biocompatible. Testing results are critical for gaining market access, ...

Cell Painting and Cell Impermeant Dye-based Assay Distinguish Effector from Target Cells One of the functions of the immune system is to recognize and destroy targets. This is accomplished by effector ...

Most cytotoxicity test “failures” trace back to controllable factors like device materials, sterilant or other chemical residues, or physicochemical characteristics of the extract - which means ...

An integrated suite of bioassays provides a coherent workflow to track antibody Fc effector activity across every stage of mAb drug development Potency assays that fail during tech transfer or ...

Explore luminescence screening assays for drug discovery, including luciferase and ATP assays. Learn the principles, formats, advantages, and limitations.

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Understanding how drug discovery screening cascades are constructed and optimized is essential for minimizing false positives ...